TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03541928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: The recommended dose for this trial is 2 g orally t.i.d. for 14 days (day 1 to day 15 and days 31 to 45). This dose has been calculated to give a similar AUC as 10 mg/kg of intravenous acyclovir administered every 8 hours. This is the same dose regimen used in a previous phase I clinical trial of ADV/HSV-tk plus acyclovir and topotecan in patients with recurrent ovarian cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: The recommended dose for Bicalutamide therapy in combination with an LHRH analogue is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that Bicalutamide be taken at the same time each day.~The use of an oral antiandrogen with medical castration for the treatment of prostate cancer is referred to as combined androgen blockade (CAB). Compared with LHRH-agonist monotherapy, CAB with bicalutamide did not reduce overall QoL but provided an early improvement in QoL related to lower urinary tract symptoms and pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Leuprolide acetate 7.5 mg depot injection will be injected monthly for a total of 2 months.
Study: NCT01670877

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: -Optional at baseline and disease progression

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: -Optional at baseline and disease progression

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: -Optional at baseline and disease progression

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: -Optional at baseline and disease progression

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research blood sample
Description: -Baseline, cycle 1 day 15, cycle 2 day 1, cycle 3 day 1, day 1 of each odd cycle, end of treatment (progression)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research blood sample
Description: -Baseline, cycle 1 day 15, cycle 2 day 1, cycle 3 day 1, day 1 of each odd cycle, end of treatment (progression)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research blood sample
Description: -Baseline, cycle 1 day 15, cycle 2 day 1, cycle 3 day 1, day 1 of each odd cycle, end of treatment (progression)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research blood sample
Description: -Baseline, cycle 1 day 15, cycle 2 day 1, cycle 3 day 1, day 1 of each odd cycle, end of treatment (progression)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research blood sample
Description: -Baseline, cycle 1 day 15, cycle 2 day 1, cycle 3 day 1, day 1 of each odd cycle, end of treatment (progression)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research blood sample
Description: -Baseline, cycle 1 day 15, cycle 2 day 1, cycle 3 day 1, day 1 of each odd cycle, end of treatment (progression)
Study: NCT03541928

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy, External beam radiotherapy
Description: On day 60, patient will undergo high dose rate (HDR) Brachytherapy. The patient will have 8-14 needle catheters inserted under ultrasound guidance. CT simulation and radiation treatment planning will be performed. The needle catheters will be connected to an HDR afterloader containing an Iridium 192 source. A single dose of 1250cGy will be delivered.
Study: NCT01827748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative Autorefractor IAR-1
Description: This is an auto-refractor mounted on an operating microscope and used with the subject in a supine position

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hartmann-Shack Auto Refractor
Description: Standard auto-refractor used with subject sitting upright in front of the instrument.
Study: NCT03541928

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Description: approximately 2-3 weeks after radiotherapy completion, patient will undergo radical retropubic prostatectomy. Use of laparoscopy or robotic assistance will be at the urologist's discretion. Lymph node dissection will be performed.
Study: NCT02377544

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Study: NCT01609205

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab 40 mg eow (totally 27 doses/patient) manufactured by Abbott will be distributed as add-on therapy to DMARD
Study: NCT00511641

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires lasting up to 30 minutes.
Study: NCT01133119

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Subjects will have femoral sheaths removed under general anesthetic but without subcutaneous infiltration of bupivacaine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care plus bupivacaine
Description: Subcutaneous dose of 0.25% bupivacaine infiltrated around the entry site of the femoral artery/vein sheath, just prior to sheath removal.~Participants will receive a dose of up to 0.8mL/kg (up to 2.0 mg/kg) of 0.25% bupivacaine, with the final amount at the discretion of the physician.
Study: NCT03007095

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation of the children's social cognitive development
Description: standardized neuropsychological tests

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of the children's social cognitive development
Description: standardized neuropsychological tests
Study: NCT04677127

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Belief Model and Health Literacy Level based Education and Counseling
Description: Patients given education and counseling constructed with health belief model (perceived susceptibility, perceived severity, perceived benefits, perceived barriers, cue to action, self-efficacy). The constructed education given through groups dichotomised by health literacy levels (low/high). Groups of 11-13, had weekly educations for 6 weeks, 6 weeks of counselling and 12 week of follow-up.
Study: NCT02877498

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adaptive support ventilation
Description: Adaptive support ventilation during invasive mechanical ventilation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Volume controlled ventilation
Description: Volume controlled ventilation during invasive mechanical ventilation
Study: NCT00881504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab in combination with modified FOLFOX6.
Description: Oxaliplatin 85 mg/m2 IV on Day 1 5-FU: 400 mg/m2 IV bolus on Day 1, followed by 2400 mg/M2 over 46 hours Leucovorin: 400 mg IV Day 1 Bevacizumab: 10 mg/kg IV on Day 1 Repeat cycles every 2 weeks until death, disease progression, unacceptable toxicity, patient refusal, or treatment delay \> 4 weeks
Study: NCT02618551

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty for treatment of severe asthma
Description: Three sessions of bronchial thermoplasty are needed to treat patients. There will be 3 to 4 weeks between each procedure.~Bronchial thermoplasty procedure is performed under general anesthesia. The medical device used in this research to achieve the thermoplasty is the Alair system (class IIb medical device ; Boston scientific)~A confocal endomicroscopy will be conducted at the first and final session of thermoplasty. This examination involves analyzing and recording the structure of bronchi microscopy through a small catheter placed on the bronchus. Photographs of the bronchi will be realized.
Study: NCT03893877

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nasal cannula
Description: experimental group will be applied nasal cannula

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal mask
Description: active comparator group will be applied nasal mask
Study: NCT04512924

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced mobile app with standard of care and education
Description: Group 1 will download an enhanced mobile app that will include education and support resources related to food allergy and its management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced mobile app with standard of care, education and support resources
Description: Group 2 will download an enhanced mobile app that will include education and support resources related to food allergy and its management, a symptom monitoring and tracking system that allows mobile app users to log symptoms they may experience as caregivers of children newly diagnosed with food allergy, e.g. fatigue and anxiety, and symptom based interventions (recommendations) that may improve a caregiver's ability to self-manage experienced symptoms.
Study: NCT01665534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High salt intake
Description: During the high salt intake period, patients received a 10-20 mmol sodium diet plus sodium tablets (180 mEq/die) to achieve a 200 mmol intake /day for two weeks
Study: NCT01571232

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone intravitreal implant
Description: Ozurdex, 0.7 mg intravitreal dexamethasone implant, given at initial visit and at month 4 (visit 5)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravitreal bevacizumab
Description: Avastin, 1.25 mg intravitreal bevacizumab, given at initial visit and Q1month for a total of 5 treatments.
Study: NCT00771615

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK A/turkey H5N1 Influenza vaccine
Description: One dose administered intramuscularly (IM) in the deltoid region. Different formulations are tested.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK A/turkey H5N1 Influenza vaccine
Description: One dose administered intramuscularly (IM) in the deltoid region. Different formulations are tested.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK A/turkey H5N1 Influenza vaccine
Description: One dose administered intramuscularly (IM) in the deltoid region. Different formulations are tested.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK A/turkey H5N1 Influenza vaccine
Description: One dose administered intramuscularly (IM) in the deltoid region. Different formulations are tested.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK A/turkey H5N1 Influenza vaccine
Description: One dose administered intramuscularly (IM) in the deltoid region. Different formulations are tested.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK A/turkey H5N1 Influenza vaccine
Description: One dose administered intramuscularly (IM) in the deltoid region. Different formulations are tested.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK A/turkey H5N1 Influenza vaccine
Description: One dose administered intramuscularly (IM) in the deltoid region. Different formulations are tested.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK A/turkey H5N1 Influenza vaccine
Description: One dose administered intramuscularly (IM) in the deltoid region. Different formulations are tested.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK A/turkey H5N1 Influenza vaccine
Description: One dose administered intramuscularly (IM) in the deltoid region. Different formulations are tested.
Study: NCT02975947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Humidified, warmed CO2 insufflation of open peritoneum using Fisher & Paykel's HUMIGARD (Fisher & Paykel Healthcare Ltd, Auckland, New Zealand)
Description: The study group will receive warmed (37°C), humidified (98% RH) carbon dioxide into the open peritoneal cavity using the Fisher \& Paykel's HUMIGARD system (Fisher \& Paykel Healthcare Ltd, Auckland, New Zealand). This will create a local atmosphere of 100% carbon dioxide (warmed, humidified) in the open peritoneal cavity.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard heating
Description: Standard intraoperative warming measures including heated blankets, heating with forced warmed air, warming of fluids, and insulation of limbs and head
Study: NCT02181855

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Full-thickness gastroplication (GERD-X)
Description: Endoscopic full-thickness gastroplication wit the GERD-X device
Study: NCT03044821

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open-Uterus Fetal Repair
Description: Single arm study. All patients will receive the open-uterus fetal repair.
Study: NCT02377544

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01324089

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: Resveratrol 2.5 grams

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose
Description: Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose
Description: Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose
Study: NCT03345407

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ELLIPTA
Description: Placebo will be administered via oral inhalation route once daily in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemiralisib ELLIPTA 50 µg
Description: Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 50 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemiralisib ELLIPTA 100 µg
Description: Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 100 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
Study: NCT00796757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 10mg/kg iv infusion every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon alfa-2a
Description: 3 MIU sc t.i.w.
Study: NCT02158208

Intervention type: OTHER
Intervention: Blood sample drawn into a 5 mL dry tube at the diagnosis and after 3 months of treatment

Intervention type: OTHER
Intervention: 16 blood samples drawn into 6 mL heparinized tubes at the diagnosis and after 3 months of treatment
Study: NCT03345407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemiralisib ELLIPTA 250 µg
Description: Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 250 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemiralisib ELLIPTA 500 µg
Description: Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 500 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemiralisib ELLIPTA 750 µg
Description: Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 750 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
Study: NCT02158208

Intervention type: OTHER
Intervention: Blood sample drawn into a 5 mL dry tube

Intervention type: OTHER
Intervention: 16 blood samples drawn into 6 mL heparinized tubes
Study: NCT03852979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: weekly paclitaxel 80 mg/m2 for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: weekly carboplatin AUC=2 for 12 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conisation
Description: if tumor is reduced to \<2 cm, patients will be treated with a conisation
Study: NCT00296153

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3-acid ethyl esters 90
Description: Omacor capsule 1000mg x 4 per day. Duration 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3-acid ethyl esters 90
Description: Omacor capsule 1000mg x 4 per day. Duration 12 weeks
Study: NCT04401878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sphenopalatine Ganglion Block using 2% lidocaine
Description: Sphenopalatine Ganglion Block is performed by a hollow culture swab that is connected with a 21-gauge syringe filled with three ml 2% lidocaine, inserted parallel to the floor of the nose until resistance is felt. The swab is at the posterior pharyngeal wall superior to the middle turbinate. The applicator was kept in the nostril for five to ten mins. The same procedure is done also in the second nostril. The patients are then examined by TCD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sphenopalatine Ganglion Block using 2% lidocaine
Description: Sphenopalatine Ganglion Block is performed by a hollow culture swab that is connected with a 21-gauge syringe filled with three ml 2% lidocaine, inserted parallel to the floor of the nose until resistance is felt. The swab is at the posterior pharyngeal wall superior to the middle turbinate. The applicator was kept in the nostril for five to ten mins. The same procedure is done also in the second nostril. The patients are then examined by TCD.
Study: NCT03345407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol (Salbutamol) MDI or nebules
Description: Albuterol (Salbutamol) MDI or nebules will be provided to all subjects as a rescue medication.
Study: NCT00085189

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tyrosinase peptide
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tyrosinase peptide
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant MAGE-3.1 antigen
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant MAGE-3.1 antigen
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: multi-epitope melanoma peptide vaccine
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: multi-epitope melanoma peptide vaccine
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: Given SC
Study: NCT01500070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Everolimus-Eluting Stent (PROMUS ELEMENT)
Description: PROMUS ELEMENT Everolimus-Eluting Stent System (Boston Scientific) or PROMUS ELEMENT PLUS Everolimus-Eluting Stent System (Boston Scientific).
Study: NCT01098409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium nitrite
Description: 0.2mcg/kg/min or 1mcg/kg/min intravenous for 30minutes at 1ml/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium nitrite
Description: 0.2mcg/kg/min or 1mcg/kg/min intravenous for 30minutes at 1ml/min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride
Description: intravenous 0.9% sodium chloride over 30minutes at 1ml/min
Study: NCT00085189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51 VG
Description: Given SC
Study: NCT00950456

Intervention type: BIOLOGICAL
Intervention: H1N1 Pandemic Influenza Vaccine (whole virion, Vero Cell-derived, inactivated)
Description: It is anticipated that subjects will receive two intramuscular injections approximately 3 weeks apart. The vaccine will be provided in two doses, one for adults, the other for children.
Study: NCT04697615

Intervention type: DEVICE
Intervention: Algometry
Description: The evaluation with the algometer was carried out in the same way by the two examiners, who held the instrument with the dominant hand, in order to adjust and coordinate the movements, while the non-dominant hand was used to stabilize the participant's skin, providing more security, avoiding thus small deviations. The pressure was applied at an angle of 90 ° (between the tool surface and the evaluated point), the rate of pressure increase was approximately 2 kg / cm² / s (kilogram per centimeter squared per second), up to the level that the participant reported a change in the sensation of pressure to a sensation of discomfort and immediately the examiner removed the device from the positioned location.
Study: NCT01198314

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immunosuppression withdrawal
Description: tapering off immunosuppressant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continue of taking immunosuppressant
Description: maintain immunosuppression
Study: NCT01799603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: TMC435, 100 milligram oral capsule will be administered on Day 1 of each treatment period, separated by washout period of 9 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: TMC435, 100 milligram oral capsule will be administered on Day 1 of each treatment period, separated by washout period of 9 days.
Study: NCT01431157

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nocturnal nasal oxygen
Description: Nasal oxygen at 2 l/min will be given at night

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No nasal oxygen
Description: Patients will have no intervention for sleep apnea
Study: NCT01501721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Home-based exercise program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Nutritional counseling aiming to reduce suggar intake
Study: NCT01435720

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SNS01-T
Description: 0.05 mg/kg twice weekly x 6 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SNS01-T
Description: 0.2 mg/kg twice weekly x 6 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SNS01-T
Description: 0.375 mg/kg twice weekly x 6 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SNS01-T
Description: 0.0125 mg/kg twice weekly x 6 weeks